Wait, It Costs How Much? Biotech Balances Optimism, Uncertainty For 2018 – Prosyscom Tech


Forbes

Wait, It Costs How Much? Biotech Balances Optimism, Uncertainty For 2018
Forbes
Many think it paid too much for Impact, and more are asking if, facing the future patent expiration of top drug Revlimid, the biotech giant needs to do a bigger deal. Many investors wanted them to buy Bluebird Bio, the gene therapy company. Regardless

قالب وردپرس

You might also like More from author

Comments are closed.

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address